Search
Jan 11, 2023
The latest on immunotherapy with John Connolly.
Parker Institute's John Connolly provides an update on the latest in cancer immunotherapy at #JPM23.
Jan 11, 2023
Talking BCMA CAR-T at #JPM23
Arcellx CMO Chris Herry talks about BCMA CAR-T for multiple myeloma at #JPM23.
Jan 11, 2023
Antibody-drug conjugates with David Epstein
Seagen's David Epstein talks about antibody-drug conjugates at #JPM23.
Jan 11, 2023
AI in biotech with Generate Biomedicines’ Mike Nally
Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.
Jan 10, 2023
Justin Zelin's take on #JPM23 news.
BTIG biotechnology analyst Justin Zelin gives his take on the news at #JPM23.
Jan 10, 2023
Stéphane Bancel discusses Moderna's personalized cancer vaccine at #JPM23
Moderna CEO Stéphane Bancel discusses his company's personalized cancer vaccine on Day Two of #JPM23 in San Francisco.
Jan 10, 2023
A top biotech dealmaker on the M&A outlook for 2023
Centerview Partners' Eric Tokat talks about the M&A deals that have been announced at #JPM23.
Jan 9, 2023
TCR therapies as a new modality in cancer treatment
Immunocore's Bahija Jallal talks about TCR based therapies at #JPM23.
Jan 9, 2023
Luke Timmerman at #JPM23
Luke Timmerman fills us in on the latest at the Timmerman Report and his upcoming climb for cancer research of Mount Kilimanjaro at #JPM23.
Jan 9, 2023
How a16z invests in healthcare
Jorge Conde tells us about a16z's philosophy for investing in healthcare at #JPM23.
Jan 9, 2023
Noubar Afeyan discusses the year ahead
Flagship Pioneering’s Noubar Afeyan gives his take on the biotech sector for the year ahead at #JPM23.
.png){kind=logo}
